Martin Sipkoff
MANAGED CARE March 2009. ©MediMedia USA

Medications that lower cholesterol and manage diabetes account for $38.1 billion — the single largest category

A recent analysis by the federal Agency for Healthcare Research and Quality (AHRQ) of the spending patterns of adult Americans on prescription drugs found that in 2006, medications affecting metabolism, accounted for $38.1 billion — the single largest category, accounting for 18.3 percent of the $208.1 billion spent on drugs that year.

The next four therapeutic classes when ranked by total expense for prescription drugs were cardiovascular agents, central nervous system agents, psychotherapeutic agents, and hormonal agents. Spending for these top five therapeutic classes totaled $130.8 billion and accounted for 62.8 percent of total expenditures on prescription drugs by the adult population in 2006.

Top five classifications of prescription drugs in 2006

Using data collected through a household survey of outpatient prescription drug purchasing patterns in 2006, the federal Agency for Healthcare Research and Quality found that the most money was spent on metabolic drugs, but the most popular drugs are central nervous system agents.

Analysis of AHRQ data

  Ranking criteria
Drug classification $ total expense (billions) % total expense % of adults having an expense within classification Average expense per prescription in classification
1. Metabolic agents $38.1 18.3 28.9 $86.90
2. Cardiovascular agents $33.1 16.0 38.9 $46.54
3. Central nervous system agents $28.2 13.5 45.5 $62.59
4. Psychotherapeutic agents $17.5 8.4 16.9 $91.54
5. Hormonal agents $14.0 6.8 29.7 $48.15

Source: Center for Financing, Access, and Cost Trends, AHRQ, Household Component of the Medical Expenditure Panel Survey, 2006

Although metabolic agents were the largest category, 45.5 percent of the adult population with a prescribed drug expense in 2006 purchased a central nervous system agent, which includes analgesics. The next most popular category was cardiovascular agents (38.9 percent).

Psychotherapeutic agents had the highest average expense per prescription ($91.54), almost double the average expense of the therapeutic class with the lowest average expense, cardiovascular agents ($46.54).

The AHRQ report provided no analysis of why these five classifications represented two-thirds of the money Americans spent on prescription drugs in 2006 (the latest year for which data based on therapeutic class are available), but analysis by members of the National Health Statistics Group (NHSG) at the Centers for Medicare & Medicaid’s Office of the Actuary point to two concurrent trends which help explain why drugs in these categories are popular: An aging population and the implementation of the Medicare Part D drug benefit.

The Census Bureau projects a 147-percent increase in the 65-and-over population between 2000 and 2050. In comparison, the population as a whole will have grown only 49 percent. Heart disease and diabetes drugs, for example, are associated with the accelerating incidence rate of chronic disease associated with aging.

Part D

The implementation of Part D has in itself led to an increase in overall health care spending, including a significant increase in prescription drug expenditures. According to NHSG analysis, in the period covered by the AHRQ drug classification report, health care spending increased 6.7 percent to $2.1 trillion, or $7,026 per person.

Prescription drug spending growth accelerated in 2006 to 8.5 percent, “partly as a result of Medicare Part D’s impact,” according to the NHSG analysis. “Most of the other major health care services and public payers experienced slower growth in 2006 than in prior years. The implementation of Medicare Part D caused a major shift in the distribution of payers for prescription drugs, as Medicare played a larger role in drug purchases than it had before. Growth in retail drug spending accelerated in 2006 to 8.5 percent from a recent low of 5.8 percent in 2005,” according to NHSG analysis of 2006 health care spending published in 2008 in Health Affairs in an article titled “National Health Spending in 2006: A Year of Change for Prescription Drugs.” (Part D was implemented in 2006.)

However, a 2009 NHSG report also published in Health Affairs pointed to a decrease in the rate of growth in prescription drug spending after the 2006 bump. That report attributes the decline in the rate of growth of spending on prescription drugs from 8.5 percent in 2006 to 4.9 percent in 2007 (the slowest rate of growth increase since 1963) to the increase in availability of generic drugs and the aggressive marketing of generic alternatives by Part D insurers.

That is certainly true with regard to the therapeutic classifications listed in the February 2009 AHRQ study. A generic alternative to Merck’s Zocor, a top-selling lipid-lowering agent, became available in late 2006, as did a generic alternative to Pfizer’s Zoloft, a top-selling antidepressant.

Generic alternatives coming to market in all five AHRQ therapeutic categories (including generic alternatives to Lipitor and Nexium now making their way through court challenges) are expected to continue to help limit the rate of cost growth in all the prescription drug classifications in the AHRQ report, according to NHSG officials.

Cancer drugs

But in one significant category not in the AHRQ report, which only examined the top five therapeutic classes, a decline in the rate of growth in drug costs resulting from generic alternatives could be offset. The rate of cost growth in cancer drugs is expected to accelerate, according to a study in the February 2009 issue of the New England Journal of Medicine.

“I believe the growth can be attributed primarily to a unique legislative and regulatory framework that shields cancer drugs (as well as a few other specialty drugs) from the strategies that health care payers such as Medicare typically use to hold down the price and utilization of drugs and other health care goods,” said the article’s author, Peter Bach, MD, of the Health Outcomes Research Group of the Memorial Sloan-Kettering Cancer Center.

Bach, and others, believe, however, that the laws covering these specialty drugs will be addressed as their costs continue to rise.

“There is no doubt that across all therapeutic categories, payers, including Medicare, will seek to control overall costs,” says Haiden Huskamp, PhD, of the Department of Health Care Policy at Harvard Medical School. “Whether it is formulary control or an aggressive push toward generics, the rate of growth in the overall costs of prescription drugs can be expected to decelerate.”

For further reading

The AHRQ report “The Top Five Therapeutic Classes of Outpatient Prescription Drugs Ranked by Total Expense for Adults Age 18 and Older in the U.S. Civilian Noninstitutionalized Population, 2006” is available at http://www.meps.ahrq.gov/mepsweb/data_files/
publications/st232/stat232.pdf

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.